Prof. Stephen Nicholls (Professor of Cardiology, Monash University, Melbourne, Australia) kindly shared his thoughts on the impact of PCSK9 inhibitors on lipid-lowering therapy, the effects of statins on coronary atherosclerotic plaques and the HUYGENS study from the virtual ESC Congress 2021.
Questions
- What has been the impact of PCSK9 inhibitors on lipid-lowering therapy, and what questions remain unanswered? (0.12)
- What have optical coherence tomography (OCT) studies taught us about the effects of statins on coronary atherosclerotic plaques? (0.48)
- What were the aims and design of the HUYGENS study? (2.13)
- What have been the study findings to date? (2.54)
- What are the clinical implications of these findings? (4.23)
Speaker disclosures: Prof. Stephen Nicholls wishes to disclose research support and consulting for Amgen and Sanofi-Regeneron.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Professor Stephen Nicholls as a highlight of ESC 2021, September 2021.
